Prefer denosumab over intravenous bisphosphonate for HCM
STEP 1 — Gather Information
Confirm hypercalcemia of malignancy (elevated serum calcium with malignancy history). Collect serum calcium, albumin-adjusted calcium, renal function (eGFR, creatinine), vitamin D level, prior antiresorptive exposure, and assess for symptoms severity.
STEP 2 — Rule In / Rule Out
Rule out severe hypercalcemia (albumin-adjusted SCa >14 mg/dL) requiring initial combination therapy with calcitonin plus an antiresorptive. If severe, proceed to combination therapy per Recommendation 3; otherwise continue.
STEP 3 — Classify or Stratify
Assess for refractory/recurrent HCM after prior intravenous bisphosphonate. If refractory/recurrent, denosumab is still preferred per Recommendation 4. If not refractory, proceed to preference decision.
STEP 4 — Decide
Choose denosumab (120 mg subcutaneously) over an intravenous bisphosphonate (e.g., zoledronic acid 4 mg or pamidronate 60–90 mg) as the initial antiresorptive for HCM.
Clinical Guardrails / Mimics / Pitfalls
Monitor serum calcium, phosphorus, magnesium, and renal function before and after denosumab; correct vitamin D deficiency and hypocalcemia prior to dosing. Avoid denosumab in patients with eGFR <30 mL/min without dose adjustment and close calcium monitoring. Do not delay antiresorptive therapy while awaiting oncology consultation; hydration remains first-line. Be aware of rare osteonecrosis of the jaw and atypical femoral fractures with long-term use.
Concrete Clinical Example
A 58-year-old man with metastatic prostate cancer presents with fatigue and nausea; serum calcium 13.0 mg/dL (albumin-adjusted), eGFR 55 mL/min, vitamin D insufficient. He asks which antiresorptive to start. Following the skill, administer denosumab 120 mg subcutaneously, supplement vitamin D, recheck calcium in 48–72 hours, and continue monthly dosing.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, DOI: 10.1210/clinem/dgac621